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The seminal event in the discovery of the renin system was
an experiment in 1898 by Tigerstedt and Bergman (1), who
produced a pressor response by injecting crude rabbit kidney
extracts into anesthetized animals. Angiotensin-converting
enzyme (ACE), a dicarboxy peptidase, was first described in
1956 by Skeggs et al. (2) while trying to purify angiotensin
(ANG). The description of insertion/deletion polymor-
phism for the ACE gene and its role in determining
variations in the physiologic activity of ACE was first
described by Rigat et al. (3) in 1990. The critical role of
ACE in the production of ANG II led to the development
of specific inhibitors of ACE. In 1968, Bakhle (4) reported
that the bradykinin (BK) potentiating factor of snake venom
inhibited the conversion of ANG I to ANG II. Work by
Vane (5) led to the synthesis of the nonapeptide, teprotide,
by Ondetti et al. (6) and eventually to the synthesis of
captopril.
See page 767
OVERVIEW OF ACE AND ACE INHIBITORS
The ACE is a 150–180-kDa ectoenzyme that is expressed
in many tissues, including vascular endothelium, renal
proximal tubular endothelium, the heart, the lung, activated
macrophages and several regions of the brain (7). Studies of
recombinant full-length ACE have shown that the apparent
Km of ACE for BK is substantially lower than it is for ANG
I (8), indicating more favorable kinetics for the hydrolysis of
BK than for the conversion of ANG I to ANG II. In most
tissues, including the heart, the messenger ribonucleic acids
for the production of all components of the renin–
angiotensin system (RAS) have been demonstrated, and the
rate-limiting step in the ANG II cascade is plasma renin
activity (9). It would appear from studies in ACE knockout
mice that essentially all the important physiologic effects of
ACE are the result of tissue rather than circulating ACE
activity (10). Other enzyme systems that can convert ANG
I to ANG II, such as chymase, are present in some tissues
(11) and may be an important source of ANG II. However,
in vitro studies have generally overestimated the potential
importance of these alternate pathways, particularly in
vascular tissues. Generally, ACE is bound to the sarco-
lemma, the site of most of the conversion of ANG I to
ANG II (12), while chymase is distributed throughout the
cell and in the interstitial space (11), physiologically less
important sites in vivo.
In nearly all cardiovascular diseases, there is an increase in
ACE activity, particularly in tissues involved in the disease
process. This includes an increase in vascular ACE activity
in hypertension (13), in plaque ACE activity in atheroscle-
rosis (14), in cardiac ACE activity in heart failure (15,16)
and in vascular and cardiac ACE activity in diabetes (17).
This upregulation of the activity of ACE can be accompa-
nied by an increase in ANG II type 1 (AT-1) receptor
density (18). Evidence from clinical studies would suggest
that patients with the D/D ACE polymorphism have
increased plasma ACE activity and that this is associated
with an increased risk of myocardial infarction (MI) and
numerous other cardiovascular diseases, such as hypertro-
phic and dilated cardiomyopathies (19,20). However, other
large studies do not support a relationship between poly-
morphisms of the ACE gene and increased cardiovascular
risk (21), such that at this time, the clinical importance of
ACE polymorphisms has been called into question. Poly-
morphisms of other components of the RAS have also been
described (22), and it may be that a combination of these
polymorphisms rather than a single polymorphism will
ultimately prove clinically important.
The ACE inhibitors have been shown to be beneficial in
a wide range of cardiovascular diseases, whether it be acute
MI, chronic heart failure (CHF), hypertension, atheroscle-
rosis or diabetes (23–26). Evidence from experimental and
clinical studies would suggest that the beneficial cardiovas-
cular effects of ACE inhibitors are the result of their effects
on both BK metabolism and the conversion of ANG I to
ANG II (27). In many disease processes, the effects of ACE
inhibitors are only clinically evident after months to years of
therapy (23,26), suggesting that these medications exert
their effects by altering the underlying pathophysiologic
process involved in the disease.
Evidence of gradual reactivation of ACE activity over
time with the use of ACE inhibitors. Several studies
would suggest that plasma ANG II levels do not remain
suppressed during chronic ACE inhibitor therapy (28,29).
Cross-sectional clinical studies also show that human tissues
can sometimes generate ANG II from ANG I during
chronic ACE inhibitor therapy (28). Although intriguing,
these reports did not initially elicit the interest they should
have because of uncertainty as to the clinical importance of
these findings. After all, the clinical benefits of ACE
inhibitors often took one to two years to be expressed, and
even when their benefits were expressed early, they were
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maintained over time (23–26). However, more recently a
number of potentially important clinical reports have helped
us refocus on this issue.
First, studies such as the Valsartan Heart Failure Trial
(ValHeft) (30) clearly indicated that the addition of an
AT-1 receptor blocker (ARB) to an ACE inhibitor in
patients with CHF resulted in both a marked decrease in
systolic arterial pressure (8 mm Hg) and in some clinical
benefit. Also, studies such as the Assessment of Treatment
with Lisinopril And Survival (ATLAS) in patients with
CHF (31), and studies indicating beneficial effects with the
addition of an ARB in patients with proteinuria (32), would
suggest that further clinical benefit can be obtained by
increasing the dose of these medications. This has helped
refocus the research community on the adequacy of ARB
and the degree of inhibition of the conversion of ANG I to
ANG II in order to obtain maximal beneficial effect.
In the study by Farquharson et al. (33) published in this
issue of the Journal, strong evidence is provided for incom-
plete blockade of the vascular conversion of ANG I to ANG
II by frequently used doses of ACE inhibitors. The inves-
tigators employed a clinical bioassay to assess the vascular
conversion of ANG I to ANG II in patients with varying
degrees of CHF using cross-sectional and longitudinal
studies; and they assessed the effects of increasing doses of
ACE inhibitors on this process. One of the advantages of
their methodology is that it assesses not only the vascular
conversion of ANG I to ANG II, but also assesses the
integrity of the whole of the ANG I signaling pathway.
Importantly, the investigators also verified the effects of
ANG II and found that the abnormalities in their patients
were essentially limited to differences in the conversion of
ANG I to ANG II and not to deregulation of other parts of
the pathway or to other potentially important systems
activated in CHF and that are modified by ACE inhibitors.
Farquharson et al. (33) did not assess the effects of other
pathways involved in the generation of ANG II; however,
this in no way invalidates or diminishes the importance of
their results. The one weakness of this methodology is that
it employs pharmacologic doses of ANG I, such that the
applicability of their findings to clinical practice is a bit
complex. The investigators essentially come to four different
conclusions.
INCREASING VASCULAR ACE ACTIVITY WITH
INCREASING CHF SEVERITY AND OVER TIME
In a cross-sectional study of patients with varying degrees of
CHF, the investigators (33) demonstrate that patients with
more severe heart failure have less suppression of the
conversion of ANG I to ANG II by ACE inhibitors than
patients with less severe CHF. This very important obser-
vation suggests that larger dose of ACE inhibitors should
perhaps be used to treat patients with more severe CHF.
The findings of Farquharson et al. (33) are compatible with
animal studies indicating that tissue ACE activity increases
in heart failure, whether the heart failure be due to volume
overload (34) or post-MI (16). This observation is particu-
larly important in clinical practice, where lower doses of
ACE inhibitors are frequently used for fear of adversely
effecting systemic arterial pressure or renal function. Al-
though the investigators (33) did not evaluate the interac-
tion of ACE activity and severity of disease with ACE
polymorphism, the effects of severity of the disease appear to
overwhelm any effect directly related to specific ACE
polymorphisms. Of course, clustering of ACE polymor-
phisms according to disease severity cannot be ruled out, as
this was not evaluated in the study (33).
The second set of studies was a longitudinal evaluation of
vascular ACE activity over an 18-month period. The investi-
gators (33) found that vascular ACE inhibition by lisinopril
was significantly reduced over time despite apparent clinical
stability of their patients. It is probable that their results
reflected upregulation of ACE activity due to a progression of
the disease rather than upregulation of ACE activity over time
due to ACE inhibitor use. First, prior to entering the study,
these patients were on a higher dose of an ACE inhibitor (16
to 17 mg) than during the study, and this for an average of 3.6
years such that any upregulation that would have resulted from
ACE inhibitor use should have long been complete. Rather,
their findings likely result from the progression of CHF over
time that has previously been described in patients with CHF,
despite the use of an ACE inhibitor (35).
FURTHER SUPPRESSION OF VASCULAR
ACE ACTIVITY WITH INCREASING DOSES
OF ACE INHIBITOR: IMPORTANCE OF TISSUE ACE
The third set of studies helps complete the first two and
clearly indicates that patients that had the least inhibition of
vascular ACE activity with lisinopril in the first set of
studies could have further suppression of vascular ACE
activity by increasing the dose of the ACE inhibitor. This
finding, coupled with the first and second set of studies,
would suggest that larger doses of ACE inhibitors may be
more effective than lower doses, and should be used in
patients with more severe heart failure. The investigators
(33) also suggest that consideration should be given to
increasing the dose of the ACE inhibitor used over time,
even if patients appear stable.
Results from the first three sets of studies by Farquharson
et al. (33) clearly provide an explanation of the results of the
ATLAS study (31) indicating a clinical benefit with the use
of larger doses of an ACE inhibitor. It is nevertheless
important to remember that the doses of ACE inhibitors
proven beneficial in clinical studies are superior to the
highest dose used in the Farquharson et al. (33) study, such
that simply using the dose of an ACE inhibitor proven to be
beneficial in clinical studies may obviate the need to increase
doses over time.
The fourth and final finding from this study would
suggest that circulating ACE activity and the effects of
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ACE inhibitors on circulating ACE activity have very little
correlation with what happens at the tissue level. These
results are compatible with studies in ACE knockout mice
indicating that all of the physiologic effects of ACE result
from tissue ACE (10) and from studies done in volume-
overloaded rats where suppression of tissue and not circu-
lating ACE activity resulted in beneficial ventricular remod-
eling (34). That tissue ACE activity is more important than
circulating ACE activity raises the question as to whether
ACE inhibitors with greater tissue affinity may prove to be
superior to those with less tissue affinity. Clearly, acute
studies of vascular reactivity by Hornig et al. (36) would
suggest that such a difference might exist. However, in large
clinical studies, benefit has been found with ACE inhibitors
regardless of tissue affinity and, unless a clinical trial
indicating superiority of one ACE inhibitor over another is
performed, any differences in ACE inhibitors related to
tissue affinity remain purely speculative. In any case, from
the study of Farquharson et al. (33), it would appear that
lack of tissue affinity can be overcome by increasing the
dose.
Thus, this study provides more information to support
the use of doses of ACE inhibitors proven to be beneficial
in clinical trials, particularly in patients with more severe
heart failure, and that increasing the dose over time may
prove beneficial, particularly if there are any signs of
progression of the disease.
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